Scholarlink

Purpose <p>To evaluate hyperreflective choroidal foci (HCF) in Sattler’s and Haller’s layers as predictive biomarkers for treatment response and pachychoroid macular atrophy (pMA) development in chronic central serous chorioretinopathy (CSC).</p> Methods <p>Retrospective analysis of 70 treatment-naïve patients with recurrent CSC classified according to Chhablani’s criteria. HCF were quantified separately in choroidal layers using spectral-domain OCT at baseline and 12-month follow-up. Patients received photodynamic therapy (<i>n</i> = 20), eplerenone (<i>n</i> = 16), or subthreshold micropulse laser (<i>n</i> = 34). Primary outcomes included treatment response (complete fluid resolution) and pMA development.</p> Results <p>At baseline, no significant differences in HCF counts existed between future responders (<i>n</i> = 36) and non-responders (<i>n</i> = 34). At 12 months, responders showed significant HCF reduction in Sattler’s layer (−9.17 foci, <i>p</i> = 0.001) and Haller’s layer (−3.19 foci, <i>p</i> = 0.039), while non-responders demonstrated increased Sattler’s foci (+4.62, <i>p</i> = 0.041). pMA developed in 15 patients (21.4%), more frequently in non-responders (32.4% vs 11.1%, <i>p</i> = 0.001). Baseline total HCF count was the strongest predictor of pMA development (β = 0.465, <i>R</i>² = 0.324, <i>p</i> &lt; 0.001), with final HCF counts showing even stronger associations (β = 0.512, <i>R</i>² = 0.348, <i>p</i> &lt; 0.001).</p> Conclusions <p>Layer-specific HCF quantification provides valuable prognostic information for treatment response and pMA risk in chronic CSC. These biomarkers may guide therapeutic decisions and identify patients requiring closer monitoring for atrophy development.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hyperreflective choroidal foci may predict pachychoroid macular atrophy development in central serous chorioretinopathy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月5日

查看全文
  • Maria Grazia Pignataro,
  • Alba Chiara Termite,
  • Enrico Borrelli,
  • Giacomo Boscia,
  • Michele Reibaldi,
  • Luisa Micelli Ferrari,
  • Giulia Ribezzi,
  • Alice Carra,
  • Stefano Dore,
  • Federica Evangelista,
  • Giovanni Alessio,
  • Francesco Boscia,
  • Pasquale Viggiano

摘要

Purpose

To evaluate hyperreflective choroidal foci (HCF) in Sattler’s and Haller’s layers as predictive biomarkers for treatment response and pachychoroid macular atrophy (pMA) development in chronic central serous chorioretinopathy (CSC).

Methods

Retrospective analysis of 70 treatment-naïve patients with recurrent CSC classified according to Chhablani’s criteria. HCF were quantified separately in choroidal layers using spectral-domain OCT at baseline and 12-month follow-up. Patients received photodynamic therapy (n = 20), eplerenone (n = 16), or subthreshold micropulse laser (n = 34). Primary outcomes included treatment response (complete fluid resolution) and pMA development.

Results

At baseline, no significant differences in HCF counts existed between future responders (n = 36) and non-responders (n = 34). At 12 months, responders showed significant HCF reduction in Sattler’s layer (−9.17 foci, p = 0.001) and Haller’s layer (−3.19 foci, p = 0.039), while non-responders demonstrated increased Sattler’s foci (+4.62, p = 0.041). pMA developed in 15 patients (21.4%), more frequently in non-responders (32.4% vs 11.1%, p = 0.001). Baseline total HCF count was the strongest predictor of pMA development (β = 0.465, R² = 0.324, p < 0.001), with final HCF counts showing even stronger associations (β = 0.512, R² = 0.348, p < 0.001).

Conclusions

Layer-specific HCF quantification provides valuable prognostic information for treatment response and pMA risk in chronic CSC. These biomarkers may guide therapeutic decisions and identify patients requiring closer monitoring for atrophy development.